| +0.005 / +0.47%|
The 4 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 3.50, with a high estimate of 6.20 and a low estimate of 1.25. The median estimate represents a +228.64% increase from the last price of 1.07.
The current consensus among 4 polled investment analysts is to Buy stock in ImmunoCellular Therapeutics Ltd. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.